Company Overview and News
WINNEMUCCA, Nev., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American: PZG) ("Paramount”) today announced it has begun the first phase of an exploration program at its 100% owned Grassy Mountain Gold Project (“Grassy”) in Eastern Oregon. The program will focus on identifying and drilling the highest priority targets with the potential to add additional resources at Grassy.
WINNEMUCCA, Nevada, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American:PZG) ("Paramount”) announced today that its Executive Chairman, John Seaberg will be presenting at the Denver Gold Forum on Tuesday September 25, 2018 at 11:30 AM Local Time in Hall ‘F’ of the Broadmoor Hotel in Colorado Springs, Colorado.
pzg-10k_20180630.htm UNITED STATES
424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-226364 PROSPECTUS 3,600,000 SHARES
WINNEMUCCA, Nev., July 31, 2018 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American:PZG) ("Paramount” or “the Company” ) reported today that the Oregon Department of Geology and Mineral Industries (“DOGAMI”) has approved and accepted seven additional baseline environmental reports, bringing the total to 12 reports approved and accepted by the appropriate state agencies. These baseline reports are required for permitting the Company’s 100%-owned Grassy Mountain gold project in eastern Oregon.
WINNEMUCCA, Nev., July 19, 2018 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American:PZG) ("Paramount”) reported today that the Oregon Department of Geology and Mineral Industries (“DOGAMI”) has approved and accepted a fifth baseline environmental report required for the permitting of Paramount’s proposed Grassy Mountain Gold Project in eastern Oregon.
WINNEMUCCA, Nev., July 16, 2018 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American:PZG) ("Paramount” or “the Company”) announced today that it has closed the previously announced (press release – June 25, 2018) non-brokered private placement funding of common stock and warrants (the “Transaction”) with accredited investors. The Company issued 2,400,000 units at $1.25 per unit for aggregate proceeds of $3,000,000.
SCHEDULE 13D CUSIP NO: 69924M 109
SCHEDULE 13D CUSIP NO: 69924M 109
Total cash operating costs of $528 per ounce of gold produced (after silver credits) Annual average production of 47,000 ounces of gold and 50,000 ounces of silver for 7.25 years After tax IRR of 28%
2018-06-29 sec.gov - 1
pzg-8k_20180625.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
pzg-8k_20180626.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET